949-98-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-3-(4-nitrophenyl)propenoic acid is used as a starting material for the synthesis of chalcones and related compounds for its anti-inflammatory and antioxidant properties. It is employed in the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
2-Methyl-3-(4-nitrophenyl)propenoic acid is used as a valuable tool in chemical research for studying the properties and reactions of chalcone derivatives and related compounds. Its unique structure allows for the exploration of new synthetic pathways and the development of novel chemical compounds.

InChI:InChI=1/C10H9NO4/c1-7(10(12)13)6-8-2-4-9(5-3-8)11(14)15/h2-6H,1H3,(H,12,13)/b7-6-

Upstream product

• 37524-18-8 p-nitro-α-methylcinnamaldehyde 
• 516-05-2 methyl-propanedioic acid 
• 555-16-8 4-nitrobenzaldehdye 
• 137-40-6 sodium proprionate 
• 123-62-6 propionic acid anhydride 
• 110-89-4 piperidine 
• 58550-34-8 (E)-2-methyl-3-(4-nitrophenyl)acrylaldehyde 
• 40277-76-7 methyl (E)-2-methyl-3-(4-nitrophenyl)acrylate 
• 55591-35-0 1,1'-(4-nitro-phenylmethanediyl)-bis-piperidine 
• 994-51-4 tetrakis-propionyloxy-silane 
• 498-23-7 citraconic acid 
• 100-05-0 4-nitrobenzenediazonium chloride 
• 127-09-3 sodium acetate 
• 67-64-1 acetone 

Downstream Products

• 21316-09-6 p-Nitro-α-methyl-zimtsaeure-p-fluorsulfonyl-anilid 
• 1879-55-6 (E)-1-nitro-4-(prop-1-en-1-yl)benzene 
• 1879-54-5 (Z)-p-nitro-(1-propenyl)benzene 
• 62-23-7 4-nitro-benzoic acid 
• 1598408-56-0 C₁₁H₁₄N₂O 
• 1598408-57-1 C₁₈H₂₀N₂O 
• 1598408-58-2 C₁₆H₂₂N₂O₂ 
• 39157-07-8 (Z)-2-Methyl-3-(4-nitro-phenyl)-acryloyl chloride 
• 1598408-35-5 1-(4-((E)-2-(methylcarbamoyl)propen-1-yl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
• 1598408-36-6 1-(4-((E)-2-(1-phenylethylcarbamoyl)propen-1-yl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
• 1598408-37-7 1-(4-((E)-2-(2,6-dimethylmorpholinocarbamoyl)propen-1-yl)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
• 103096-03-3 (±)-3-(4-aminophenyl)-2-methylpropanoic acid 
• 40277-76-7 methyl (E)-2-methyl-3-(4-nitrophenyl)acrylate 
• 53618-29-4 (E)-ethyl 2-methyl-3-(4-nitrophenyl)acrylate 

Relevant academic research and scientific papers

Discovery of a novel inhibitor of nitric oxide production with potential therapeutic effect on acute inflammation

Inflammation as a host's excessive immune response to stimulation, is involved in the development of numerous diseases. To discover novel anti-inflammatory agents and based on our previous synthetic work on marine natural product Chrysamide B, it and a series of derivatives were synthesized and evaluated for their anti-inflammatory activity on inhibition of LPS-induced NO production. Then the preliminary structure–activity relationships were conducted. Among them, Chrysamide B is the most potent anti-inflammatory agent with low cytotoxicity and strong inhibition on the production of NO (IC50 = 0.010 μM) and the activity of iNOS (IC50 = 0.082 μM) in LPS-stimulated RAW 264.7 cells. Primary studies suggested that the mechanism of action may be that it interfered the formation of active dimeric iNOS but not affected transcription and translation. Furthermore, its good performance of anti-inflammatory effect on LPS-induced multiple inflammatory cytokines production, carrageenan-induced paw edema, and endotoxin-induced septic mice, was observed. We believe that these findings would provide an idea for the further modification and research of these analogs in the future.

Design, synthesis and antitumor activity evaluation of Chrysamide B derivatives

Marine natural products derived from special or extreme environment provide an important source for the development of anti-tumor drugs due to their special skeletons and functional groups. In this study, based on our previous work on the total synthesis and structure revision of the novel marine natural product Chrysamide B, a group of its derivatives were designed, synthesized, and subsequently of which the anti-cancer activity, structure-activity relationships and cellular mechanism were explored for the first time. Compared with Chrysamide B, better anti-cancer performance of some derivatives against five human cancer cell lines (SGC-7901, MGC-803, HepG2, HCT-116, MCF-7) was observed, especially for compound b-9 on MGC-803 and SGC-7901 cells with the IC 50 values of 7.88 ± 0.81 and 10.08 ± 1.08 μM, respectively. Subsequently, cellular mechanism study suggested that compound b-9 treatment could inhibit the cellular proliferation, reduce the migration and invasion ability of cells, and induce mitochondrial-dependent apoptosis in gastric cancer MGC-803 and SGC-7901 cells. Furthermore, the mitochondrial-dependent apoptosis induced by compound b-9 is related with the JAK2/STAT3/Bcl-2 signaling pathway. To conclude, our results offer a new structure for the discovery of anti-tumor lead compounds from marine natural products.

Novel piperazine compound as well as preparation method and application thereof

The structural general formula of a novel piperazine compound is shown in the specification. The invention aims to provide a novel anti-inflammatory drug with high efficiency and low side effect. Because typical marine characteristic skeleton molecules ri

Synthesis of Albicidin Derivatives: Assessing the Role of N-terminal Acylation on the Antibacterial Activity

The peptide antibiotic albicidin, which is synthesized by the plant pathogenic bacterium, Xanthomonas albilineans, represents the most prominent member of a new class of antibacterial gyrase inhibitors. It shows remarkable antibacterial activities against Gram-positive and Gram-negative microorganisms. Its unique structure potentially represents a new lead structure for the development of an antibacterial drug. Here we report the synthesis of 14 albicidin derivatives with structural variations at the N-terminus, primarily investigating the effects of variation of cinnamoyl, phenylpropanoyl, and benzoyl residues. Gyrase inhibition in vitro and determination of minimal inhibitory concentrations were assessed in parallel. Activities in a nanomolar range and the importance of N-acylation were demonstrated.

BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES

BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therap

2,3-BENZODIAZEPINES

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

2, 3-benzodiazepins

What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.

BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES

BET-protein-inhibitory, in particular BRD4-inhibitory bicyclo- and spirocyclically substituted 2,3-benzodiazepines of the general formula (I), pharmaceutical compositions comprising the compounds according to the invention, and the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders, are described. Furthermore, the use of BET protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control is described.

Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents

A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MTT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 μM against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 μM), representing a promising lead for further optimization.

Multifactorial control of iteration events in a modular polyketide assembly line

Freedom and control: First insights into the rare programmed iteration of an individual polyketide synthase (PKS) module were obtained from the analysis and mutation of aureothin (1) synthase. The first ketosynthase (KS) domain primes the PKS, allowing intermediate retrotransfer. Addition of a designated loading module results in a complete loss of iteration. The downstream KS functions as a gatekeeper for correct chain length. Copyright